SCHEMBL979259

SCHEMBL979259

CC(C)(C)OC(=O)N1C(=O)CCC[C@H]1c1cc(F)cc(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.40
BRD3 Q15059 2/20 0.36
DPP4 P27487 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
HTR7 P34969 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
ELANE P08246 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1273810 0.81 RIPK1 (0.39) RIPK1DPP4KDM4EMAPTTHRB
SCHEMBL981354 0.81 RIPK1 (0.36) RIPK1HTR7HCRTR1HCRTR2
SCHEMBL7236411 0.81 HTR7 (0.42) DDB1CRBNHTR7HCRTR2HDAC1
SCHEMBL22039428 0.81 HTR7 (0.42) DDB1CRBNHTR7HCRTR2HDAC1
SCHEMBL1274378 0.80 RIPK1 (0.38) RIPK1DPP4KDM4EMAPTTHRB
SCHEMBL18640948 0.78 RIPK1 (0.40) RIPK1DPP4KDM4EMAPTTHRB
SCHEMBL977719 0.76 DPP4 (0.37) RIPK1DPP4KDM4EMAPTTHRB
SCHEMBL24366649 0.75 CHRM2 (0.41) KDM4EMAPTTHRBDDB1CRBN
SCHEMBL15017885 0.75 CHRM2 (0.41) KDM4EMAPTTHRBDDB1CRBN
SCHEMBL7589379 0.75 L3MBTL1 (0.51) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893079-B2 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-02-22 US disclosed
US-20110021516-A1 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP (US) 2011-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021516-A1 MONOCYCLIC CGRP RECEPTOR ANTAGONISTS CCKAR, CALCRL, CCKBR RIPK1 3980/4885BRD3 2771/4885DPP4 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.